Nasus Pharma Ltd Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Teleman Dan Benjamin, was filed 22 Apr 2026.
Nasus Pharma Ltd: what insiders have been doing
Nasus Pharma Ltd belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). 1 insider has disclosed 2 filings since 22 October 2025.
Only purchases show up on the open market, 2 purchases in all worth €36k, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 chief executive. One trade stands out by size: a purchase of €26k from Teleman Dan Benjamin, disclosed on 1 April 2026.
Compared with its exchange (2,023 companies, median 41 filings), a count of 2 filings is below the norm. The full history, which starts in 2026, counts 2 purchases against no sales.
The last purchase on record was published on 22 April 2026, which is 200 days ago.
In the same sector, recent insider purchases at UCB also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -6.5%Entry US$3.40 · Close 16 Oct 2026 US$3.18
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 2,900 shares@ US$3.7626.1% of flowOrdinary SharesSEC:0001493152-26-018607:0Canonical exit: 21 Jul 2026 (T+90)
- 15,000 shares@ US$2.0473.9% of flowOrdinary SharesSEC:0001493152-26-014503:0Canonical exit: 29 Jun 2026 (T+90)
2 of 2 declarations
About Nasus Pharma Ltd
Nasus Pharma Ltd is a company focused on developing innovative treatments for respiratory diseases. It is listed on the XNAS market.
